FDA warns on seizure risk with Acorda's MS drug; Pfizer's Lyrica passes side-effects trials;

 @FiercePharma: Another warning from European pharma: Italian cuts could cost thousands of jobs, Farmaindustria says. Report | Follow @FiercePharma

> Acorda Therapeutics' MS drug Ampyra came in for a stepped-up seizure warning from FDA, which cited higher risks in patients with poor kidney function. Report

> Hospira ($HSP) said a supplier defect caused the recall of four cancer drugs on problems with embedded particles in their glass vials. More

> Pfizer's ($PFE) Lyrica met its targets in two clinical trials designed to assess its risks to reproductive function in men and its potential to cause discontinuation symptoms. Story

> Indian genericsmaker Dr. Reddy's Laboratories expects pressure on sales as governments continue to squeeze drug spending. Report

> India's Lupin missed earnings estimates, despite a 40% surge in U.S. sales, thanks to a bigger-than-expected tax bite. More

> A Congressional committee advanced legislation that would allow Amphastar to sell 1 million inhalers that were banned for environmental reasons last year. Report

Biotech News

 @FierceBiotech: A handful of genetic mutations drive acute leukemia transformation. Article | Follow @FierceBiotech

 @JohnCFierce: Washout. Via NYT: Bapi investigator says "absolutely no evidence at all of a clinical benefit". Report | Follow @JohnCFierce

 @RyanMFierce: Hard to find who in bio isn't using Big Data. Special Report: 10 Reasons Why Biotech Needs Big Data. Report | Follow @RyanMFierce

> Merck snags Chimerix antiviral HIV program in $168.5M deal. News

> Pfizer, J&J report ominous PhIII failure of bapineuzumab in Alzheimer's study. Article

> Forest outpaces major league rivals in race for a COPD drug approval. Story

> Sarepta extension study delivers promising results for DMD patients. Item

Medical Device News

@FierceMedDev: Siemens snagged FDA clearance for a new MRI scanner the company says is more cost-effective than its competitors. Release | Follow @FierceMedDev

 @MarkHFierce: A new study connects increased heart attack risk with total hip and knee replacement surgery. More | Follow @MarkHFierce

 @DamianFierce: The FDA has slapped CareFusion with another Class I recall over leaky ventilators. Story | Follow @DamianFierce

> As health costs rise, 'generic' devicemakers see opportunity. More

> Histogenics reels in $49M Series A for tissue engineering implants. News

> CareFusion hit with another Class I ventilator recall. Article

> As health costs rise, 'generic' devicemakers see opportunity. Story

Pharma Manufacturing News

> Owens & Minor buys unit from wholesaler Celesio. More

> Strides Arcolab to expand manufacturing in Africa with French investment. Report

> Drugmakers played unintended role in counterfeits hitting U.S. Article

> New Florida drugmaker springs from debacle of another. Story

> NZ doc faces 30 years after fake Cialis conviction. News

Biotech Research News

> Novel class of Alzheimer's drugs looks promising in animals. Story

> A handful of genetic mutations drive acute leukemia transformation. Article

> One molecule may stand in the way of liver cancer. Report

> Genetic mutations linked to childhood brain cancer subtypes. More

And Finally... A three-drug cocktail showed promise in treating resistant tuberculosis, a growing threat around the globe. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.